As ketamine therapy has become more widely available across the United States, providers have increasingly turned to digital marketing and social media to reach prospective patients. While patient education and outreach are a vital part of the success of any medical practice, ketamine’s status as a medication that is widely prescribed for off-label usage creates unique marketing considerations for mental health providers. Without a carefully tailored marketing plan, even one statement that could be construed as misleading or inaccurate in a social media ad can open the door to significant legal exposure. For many providers offering ketamine therapy, staying ahead of marketing risks is crucial to prevent your practice from regulatory scrutiny.
The Problem With “Cure” Language
The media buzz around ketamine’s potential to treat a variety of medical conditions has only grown in recent years. In particular, several studies have shown positive outcomes for patients with severe depression. Despite these promising indicators, one of the most common missteps providers make in advertising is using overly definitive language. Aggressive marketing hooks, including promises to “cure” a patient’s depression, provide “immediate relief,” or “guarantee results” are the types of “red flag” language regulators look for when evaluating providers’ marketing practices.
Providers also frequently land themselves in hot water when describing the risks of ketamine therapy. As of 2026, ketamine remains an off-label treatment for most psychiatric conditions. Because the FDA has not approved ketamine specifically for depression treatment (aside from REMS-regulated esketamine), regulators view claims that ketamine infusion therapy is “FDA-approved” or “FDA-cleared” as highly misleading, as they can lead patients to make evaluations of the safety and risks of ketamine therapy without accurate or complete information. Providers who base their marketing on evidence-based descriptions, rather than promising outcomes, are less likely to invite regulatory scrutiny.
State Consumer Protection and Advertising Laws
State-level regulators are some of the most aggressive when it comes to policing provider marketing materials. Specifically, state attorneys general regularly pursue investigations into deceptive or misleading marketing practices as potential violations of state consumer protection laws, which protect consumers from deceptive marketing practices. Providers can be held liable for violations of these laws not only for traditional marketing materials, but also for website content, social media, testimonials from former patients, and even email marketing campaigns. Even state licensing boards can pursue disciplinary actions for providers who fail to provide relevant risk information in their marketing content, which can range from minor fines to licensure revocation.
Improper Use of Testimonials and Influencer Marketing
Providers know that word of mouth can be crucial to developing a strong practice. Today, many ketamine clinics use patient testimonials and influencer partnerships to promote their services. But as with any marketing materials, providers must carefully review the content of any patient or influencer endorsements before they are posted. While both can be valuable tools to help educate prospective patients, statements that exaggerate the effects of treatment or provide incomplete information about the risks of treatment invite regulators to come knocking. Statements describing dramatic improvements should be balanced with appropriate disclaimers noting that individual results can vary to ensure prospective patients are meaningfully informed before any treatment takes place.
Health Law Alliance: Your Trusted Partners
Ketamine providers face a mountain of regulatory challenges in today’s legal landscape. With the explosive growth of ketamine infusion clinics, providers across the country are having to grow their businesses with little concrete guidance, all while state and federal regulators circle the waters. But with the right guidance, marketing compliance doesn’t have to be complicated. With decades of experience advising healthcare providers in regulatory matters, our attorneys at Health Law Alliance know how to help you navigate complex regulatory frameworks with ease. Contact us today for a free consultation.
MORE ARTICLES BY CATEGORY
OMIG Audit Defense New York: What the 2026 Work Plan Means for Providers
Every year, the New York Office of the Medicaid Inspector General (OMIG) releases its Work Plan outlining enforcement priorities. The 2026 plan sends a clear signal that Medicaid providers in New York are entering a far more aggressive enforcement environment.
Read More >>PBM Member Denial Audit Findings: A Growing Threat to Pharmacies
Pharmacies undergoing a Pharmacy Benefit Manager (PBM) audit are typically prepared to address inventory discrepancies and documentation issues. What many are not prepared for, however, is the increasing use of PBM member denial findings, allegations that a patient claims they did not receive and/or did not authorize the dispensing of a medication for which a claim was submitted.
Read More >>From Minor PBM Audit Finding to Major Liability: How Small Issues Trigger Big Consequences
Pharmacies often approach a PBM audit with the understanding that small discrepancies and modest recoupments are simply part of doing business. In today’s enforcement landscape, that assumption is no longer safe.
Read More >>HLA’s Latest PBM Win Highlights the Dangers of Inventory Discrepancies
Inventory discrepancies are one of the first things PBMs look for during an audit. Even minor clerical errors like entering the incorrect NDC or failing to return a medication to stock can snowball, creating major financial risks that could place your pharmacy in jeopardy.
Read More >>